Literature DB >> 2117474

Interferon gamma encapsulated into liposomes enhances the activity of monocytes and natural killer cells and has antiproliferative effects on tumor cells in vitro.

I Rutenfranz1, A Bauer, H Kirchner.   

Abstract

The effects of human interferon gamma (IFN gamma) encapsulated into liposomes were investigated in vitro. Monocytes were induced to release a cytotoxic factor with either IFN gamma encapsulated into liposomes, free IFN gamma or lipopolysaccharide (LPS). If IFN gamma was applied in the liposomal form, less IFN activity was required to stimulate monocytes. Most of the cytotoxic factor was secreted during the first 4 h of stimulation. The cytotoxic factor in supernatants from PMNLs was completely neutralized by a monospecific polyclonal antiserum to tumor necrosis factor (TNF). Combining subthreshold doses of IFN gamma liposomes or IFN gamma with lipopolysaccharide synergistically enhanced the release of TNF. In fluorescence analysis, altered expression of the class II HLA-DR antigen on LeuM3 positive monocytes was induced with IFN gamma liposomes as well as with IFN gamma. Not only monocytes but also natural killer (NK) cells were stimulated to higher cytotoxicity by IFN gamma liposomes in a dose-dependent manner. In comparison with IFN gamma, the same amount of activity was necessary for adequate stimulation of NK-cells against the K562 target cells. Furthermore, the antiproliferative effects of IFN gamma liposomes and free IFN gamma on several human tumor cell lines was compared. Among several cell lines tested, U937 and A549 turned out to be sensitive to IFN gamma, and both cell lines reacted with 50% growth inhibition at a lower amount of gamma presented by liposomes than in the free form. These data show production of IFN gamma liposomes which possess immunomodulatory and antiproliferative activity in vitro. In several of the test systems studied, liposome-encapsulated IFN gamma was more effective than free IFN gamma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117474     DOI: 10.1007/bf01739431

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  29 in total

1.  Biological effects of gamma-interferon on human tumor cells: quantity and affinity of cell membrane receptors for gamma-IFN in relation to growth inhibition and induction of HLA-DR expression.

Authors:  U Ucer; H Bartsch; P Scheurich; K Pfizenmaier
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

2.  Synergistic activation of macrophages by lymphokine and lipopolysaccharide: evidence for lymphokine as the primer and interferon as the trigger.

Authors:  R M Schultz
Journal:  J Interferon Res       Date:  1982

3.  Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects.

Authors:  J Ferluga; H U Schorlemmer; L C Baptista; A C Allison
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

4.  Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes.

Authors:  S G Reed; M Barral-Netto; J A Inverso
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

5.  A rapid assay for cytotoxicity of unstimulated human monocytes.

Authors:  H W Ziegler-Heitbrock; G Riethmüller
Journal:  J Natl Cancer Inst       Date:  1984-01       Impact factor: 13.506

6.  Recombinant interferon-gamma (immuneron): results of a phase I trial in patients with cancer.

Authors:  M van der Burg; M Edelstein; L Gerlis; C M Liang; M Hirschi; A Dawson
Journal:  J Biol Response Mod       Date:  1985-06

7.  Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

Authors:  J L Urban; H M Shepard; J L Rothstein; B J Sugarman; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  Immune interferon: a pleiotropic lymphokine with multiple effects.

Authors:  G Trinchieri; B Perussia
Journal:  Immunol Today       Date:  1985-04

9.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.

Authors:  B Beutler; D Greenwald; J D Hulmes; M Chang; Y C Pan; J Mathison; R Ulevitch; A Cerami
Journal:  Nature       Date:  1985 Aug 8-14       Impact factor: 49.962

10.  Pharmacokinetics of recombinant human interferon-gamma in the rhesus monkey after intravenous, intramuscular, and subcutaneous administration.

Authors:  B L Ferraiolo; G B Fuller; B Burnett; E Chan
Journal:  J Biol Response Mod       Date:  1988-04
View more
  1 in total

Review 1.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.